Objectives To develop a model using radiomic features extracted from MR images to distinguish radiation necrosis from tumour progression in brain metastases after Gamma Knife radiosurgery. Methods We retrospectively identified 87 patients with pathologically confirmed necrosis (24 lesions) or progression (73 lesions) and calculated 285 radiomic features from four MR sequences (T1, T1 post-contrast, T2, and fluid-attenuated inversion recovery) obtained at two follow-up time points per lesion per patient. Reproducibility of each feature between the two time points was calculated within each group to identify a subset of features with distinct reproducible values between two groups. Changes in radiomic features from one time point to the next (delta radiomics) were used to build a model to classify necrosis and progression lesions. Results A combination of five radiomic features from both T1 post-contrast and T2 MR images were found to be useful in distinguishing necrosis from progression lesions. Delta radiomic features with a RUSBoost ensemble classifier had an overall predictive accuracy of 73.2% and an area under the curve value of 0.73 in leave-one-out cross-validation. Conclusions Delta radiomic features extracted from MR images have potential for distinguishing radiation necrosis from tumour progression after radiosurgery for brain metastases. Key points • Some radiomic features showed better reproducibility for progressive lesions than necrotic ones • Delta radiomic features can help to distinguish radiation necrosis from tumour progression • Delta radiomic features had better predictive value than did traditional radiomic features 
Introduction
Brain metastases are the most common type of intracranial tumours, occurring in 9-17% of patients with cancer [1] . Aggressive treatment of brain metastases with stereotactic radiosurgery has improved the median survival time for patients with brain metastases [2, 3] , but approximately 10% of patients receiving radiosurgery for their brain tumour develop radionecrosis [4, 5] . Necrosis typically manifests at 6-9 months after radiosurgery with oedema and severe neuropsychological disturbances; these symptoms, and the appearance of radiation necrosis on magnetic resonance imaging (MRI), closely mimic tumour progression. Because tumour progression can be treated, but radiation necrosis is irreversible, the ability to distinguish the two after stereotactic radiosurgery (e.g., Gamma Knife) for brain metastases is clinically important.
At present, confirmation of necrosis versus progression mainly relies on surgical resection, an invasive approach with risk of surgery induced neurologic deficits and other operative complications such as wound infection. Additionally, late stage cancer patients often carry medical comorbidities which can compound surgical risk. On the other hand, part of routine follow-up care after Gamma Knife treatment involves undergoing high-resolution MRI at each visit, which can include T1 weighted (T1) scans, T1 weighted post-contrast (T1c) scans, T2 weighted (T2) scans, fluid-attenuated inversion recovery (FLAIR) scans, and diffusion-weighted MR scans, among others. However, to date none of these scan types can reliably distinguish radiation necrosis from tumour progression based on lesion appearance (Fig. 1) . Other special imaging approaches [6, 7] may be useful to distinguish radiation necrosis from tumour progression, but they are not generally available.
An alternative to relying entirely on lesion appearance on various types of scans is to use the radiomic features of the MR image data. Radiomic features are quantitative descriptors that reflect textural variations in image intensity, shape, size or volume to offer information on tumour phenotype [8] [9] [10] [11] [12] [13] . Here, we explored the possibility of using radiomic features extracted from MR images for predictive modelling to distinguish radiation necrosis from tumour progression after Gamma Knife radiosurgery for brain metastases.
Materials and methods

Patient data
This retrospective analysis of data from MR images was approved by the institutional review board, and the requirement for informed consent was waived. Eligibility criteria were as follows. (a) treatment with Gamma Knife radiosurgery for brain metastases with subsequent pathologically confirmed tumour progression or radiation necrosis via histologic resection or imaging during follow-up from August 2009 through August 2016; (b) availability of at least two sets of MR scans obtained at two separate follow-up times after radiosurgery, but before confirmation; and (c) an identical sequence protocol for all MR scans, including T1, T1c, T2, and FLAIR. Patients were excluded if the MRI data were of poor quality because of motion artefacts or poor contrast injection. All MR images were acquired with a 1.5-T MRI system (Signa HDxt; GE Healthcare, Barrington, IL, USA) during routine clinical visits. All images were axial scans with field of view of 22 cm, slice thickness of 5 mm, and slice spacing of 6.5 mm. We identified 87 patients who met these criteria; one or two lesions were identified per patient, for a total of 73 tumour progression lesions and 24 radiation necrosis lesions. The outcome of the tumour resection was used to label the lesion as necrosis or tumour progression. Table 1 shows the demographic summary of patients enrolled into this study.
Prediction using radiomic features
The overall workflow of this study is depicted in Fig. 2 ; each step in the process is described further below.
Lesion segmentation Each lesion was delineated on each type of MRI sequence (T1, T1c, T2, and FLAIR) for each patient by using the VelocityAI software (version 3.0.1; Varian Medical Systems, Atlanta, GA, USA). A radiation oncologist contoured the regions of interest manually on the T1c images because the lesions were easier to identify after contrast injection than on the other scan types. The T1c contour was then rigidly mapped to the other scan sequences (T1, T2, and FLAIR) for each patient at each time point by using the Mattes mutual information metric [14] in the Velocity AI. The radiation oncologist then reviewed the contours on the T1, T2, and FLAIR scans to ensure correct mapping and modified them if necessary.
Preprocessing and feature calculation Image preprocessing and radiomic feature extraction and calculation were done with Imaging Biomarker Explorer (IBEX) (http://bit.ly/ IBEX_MDAnderson), an open-source software tool based on Matlab and C/C++ [15] . Image preprocessing to reduce uncertainty in feature analysis was done as follows [16] . First, an edge-preserving smoothing filter was applied to the tumour volume before the feature calculations [17] to preserve meaningful edge information while smoothing out undesirable imaging noise. Next, different thresholds were applied to the lesion volume on each scan type to exclude possible brain tissue and to define the final lesion volume. Based on our experience, we set the following low thresholds for image intensity values: 120 for T1; 200 for T1c; 150 for T2; and 50 for FLAIR. A total of 285 texture features were calculated for each contoured lesion. This feature calculation was done for all four scan types at the two time points, resulting in a total of 2280 radiomic features per lesion. Textural features were organized into six categories according to the feature calculation method: direct intensity and intensity histogram [18, 19] ; grey level co-occurrence matrix (COM) [20] ; grey level run length matrix (RLM) [21] ; geometric shape [22, 23] ; neighbourhood grey-tone difference matrix (NGTDM) [24] ; and (vi) histogram of oriented gradients (HOG) [25, 26] (Table 2 ). All features were calculated in the 3-dimensional (3D) volume. Some feature values in the COM, RLM, and NGTDM categories were also calculated within 2-dimensional (2D) slices of the lesion volume and then averaged over all slices; these averaged features were called 2.5D features to distinguish them from those calculated from the 3D volume.
We also calculated Bdelta^radiomic features, representing the change in features from one time point to the next, for feature modelling. These delta values were calculated for each MRI sequence, for a total of 1140 delta radiomic features per lesion. Because the time separation between the two sets of MRI scans, ΔT, was different for different patients (range, 9-119 days), these delta radiomic features were not directly comparable, and so we normalized the delta feature value to have a time separation of 30 days for all patients as follow:
where δF is the delta feature value before normalization and δF n is the delta feature value after normalization.
Feature selection Not all radiomic features are necessarily useful for distinguishing necrosis from progression; in fact, many features are noisy and may lead to overfitting or misclassification in feature modelling. The extracted features also presumably included substantial redundancy. Therefore, it is important to identify a subset of useful and unique features for feature modelling. Previous studies have reported that quantitative analysis of tumour tissues is more reproducible than quantification of necrotic tissues [27] , which led us to use concordance correlation coefficients (CCCs) to quantify the reproducibility of radiomic features for feature selection [16, 22, 28] . The CCC value ranges from -1 to 1, with 1 representing a high reproducibility, 0 no reproducibility, and -1 inverse reproducibility. We calculated the CCC values for each radiomic feature between the two time points for the Fig. 2 A generic framework for using radiomic features to create a predictive model. Steps include lesion segmentation, image pre-processing and feature extraction, and feature selection, analysis, and modelling radiation necrosis group and tumour progression group. Radiomic features with a CCC value > 0.7 for tumour progression and at the same time a CCC value between -0.1 and 0.1 for necrosis were considered potentially useful for distinguishing necrosis from progression.
Feature modelling We used two sets of features for modelling-the radiomic features at the second time point and the delta features (change from the first to the second time point).
The second time point scans were obtained close to the time of pathologic confirmation, and features from those scans may be more consistent with the actual outcomes than features obtained at the first time point. In contrast, the delta radiomic features reflected difference in features from one time point to the next for both the necrotic and progression groups. Delta radiomic features could be distinguishable based on previous reproducibility studies [27] . Radiomic features or delta radiomic features were input into five types of classifiers for modelling: decision trees; discriminant analysis; support vector machines; nearest neighbour classifiers and ensemble classifiers [29] by using the classification learner in Matlab (version 2015b, Mathworks, Natick, MA, USA). The modelling was done on the basis of the selected radiomic features in the previous step using the CCC values, to predict radiation necrosis or tumour progression. A heuristic approach was used by testing the possibility of all combinations of selected features for feature modelling. We used leave-one-out cross validation to validate the predictive models. The performance of the predictive models was evaluated by analysis of the area under the curve (AUC) of the receiver operating characteristic (ROC) and with confusion matrices, which are tables used to describe the performance of the prediction model on a set of test data for which the true values are known. Finally, we compared the prediction performance of the radiomic features at the second time point with that of the delta radiomic features. 
Results
Feature selection
Comparisons of reproducibility for all radiomic features between the necrotic lesions and the progressive lesions are shown as a heat map in Fig. 3 . Those features showing distinctly different CCCs for necrosis (-0.1 < CCC < 0.1) versus progression (CCC > 0.7) are highlighted for the COM features. Reproducibility of these features was found to be fairly high for the progressive lesions, but not for the necrotic lesions. Features considered potentially distinguishable between these two groups were then selected for subsequent modelling. We found that most radiomic features extracted from the T1, T2, and FLAIR sequences did not show sufficient separation between these two groups except the HOG skewness feature extracted from the T2. From the T1c scans, we were able to select 42 radiomic features using the criterion defined by the CCC values, and most of them are COM features (Table 2) .
Feature modelling
The ROC curves and the confusion matrices for the feature modelling are shown in Fig. 4 and Table 3 . In feature modelling, because the training data was highly skewed, with the number of the progression lesion much more than that of the necrosis lesion, we found that the best classifier for this situation was the RUSBoost [30] , an ensemble classifier in our evaluation. The RUSBoost is a decision tree based classifier. We used the following parameters for RUSBoost classifier in our evaluation: maximum number of splits as 50, number of learners as 150, and learning rate as 0.1. For the delta radiomic features, the best predictive features were the combination of two direct intensity features from T1c (energy and variance), 2 2.5D-RLM features from T1c (high grey level run emphasis and short run high grey level emphasis), and the HOG skewness feature from T2. The overall accuracy of the leave-oneout cross-validation was 73.2%, with an accuracy for predicting radiation necrosis of 58.3% and an accuracy for predicting tumour progression of 78.1%. The AUC of the ROC curve was 0.73. In contrast, for the radiomic features at the second time point, the overall accuracy of the leaveone-out cross validation for those features was 69.1%, with an accuracy for predicting radiation necrosis of 54.2% and an accuracy for predicting tumour progression of 74.0%. The AUC of the ROC curve was 0.65.
Discussion
We developed a predictive model based on radiomic features extracted from MR images to distinguish radiation necrosis Distinct CCC values between these two groups were highlighted for the COM features. Abbreviations: IHIST, direct intensity and intensity histogram; COM, grey level co-occurrence matrix; RLM, grey level run length matrix; SHAPE, geometric shape; NGTDM, neighbourhood grey-tone difference matrix; HOG, histogram of oriented gradients from tumour progression after Gamma Knife radiosurgery for brain metastases. Previous studies on feature reproducibility for necrotic tissue [27] led us to propose using CCC values for feature selection, both to reduce redundancy and identify features useful for predictive modelling. We found this feature selection approach to be effective, and believe that our findings will be a useful addition to radiomics research on identifying features that are useful for outcome modelling for clinical applications.
The major finding of this study was that the delta radiomic features extracted from T1c MR images had great potential for distinguishing radiation necrosis from tumour progression for patients treated with Gamma Knife radiosurgery. Because of the unbalanced of the training data and the relatively small amount of the training data, it was difficult to conclude whether a predictive model could be developed to reliably predict the outcome. However, we did find that radiomic features extracted from T1c were more valuable than those extracted from other MR sequences in this study (T1, T2, and FLAIR). In future studies of using imaging features to distinguish radiation necrosis from tumour progression, the features identified in this study should be investigated first for their predictive value.
To the best of our knowledge, we are the first to use MRbased delta radiomic features to distinguish radiation necrosis from tumour progression after Gamma Knife radiosurgery for brain metastatic lesions. Distinguishing between these two conditions is challenging and is the focus of considerable research in the field of neuro-oncology. However, many published studies seek to develop new imaging approaches to improve diagnosis, such as MRI spectroscopy and perfusion MRI [6] , dynamic contrast-enhanced MRI [31] , and positron emission tomography imaging [7] , among others. Although these studies are important, these approaches are generally expensive and require considerable development before clinical use. Some investigators have used radiomic features to distinguish radiation necrosis from tumour progression [10, 12, [32] [33] [34] , but those studies used radiomic features obtained at a single time point instead of using changes in radiomic features over time to model or classify features. Because radiomic features seem to keep changing over time, determining the best time to extract features for modelling is difficult, and models built on these features may not be sufficiently robust to account for variations over time. Our study found that delta radiomic features had higher predictive value than did radiomic features extracted from a single time point. Our approach may also be useful as a noninvasive way of determining the status of an enlarging lesion after radiosurgery, as well as aiding the choice of therapy once a lesion has been detected (e.g., surgical resection versus conservative medical management). Our study had some limitations. First, the progression group had twice the data samples than the necrosis group. This imbalance greatly skewed the outcome of feature modelling for most classifiers limiting the predictive capability and accuracy. The limited numbers of lesions (and patients) reflected the nature of the treatment. We plan to add more data samples to our model when new patient data become available. Second, although patients were asked to return for scheduled follow-up visits, the follow-up interval varied among patients, and thus the time separation for calculating the delta radiomic features was different among patients. In an attempt to mitigate this limitation, we scaled the time interval to 30 days for all patients, under the assumption that if the radiomic features changed, that change would be linear during that period. This may be an oversimplification; although the assumption is reasonable, it may not be consistent with the actual changes in features, which are unknown at this time.
Including data samples at additional time points could potentially address this problem. Third, uncertainties were present in our analysis that could have affected the outcomes. The boundaries of the actual lesion were not known. Lesion segmentation was based on the best judgment of the radiation oncologists and could have varied among individuals. Unlike CT images, MR image values are not calibrated, and thus the same tissue could appear different on different MRI systems. Although some have proposed ways of normalizing MR intensity values [35] , the efficacy of normalization is not known. Hence, rather than using normalization, we chose threshold values for intensity of the lesion volume based on our experience, acknowledging that contrast-enhanced MR scans might not be suitable for intensity normalization. Finally, implementation of current radiomic analysis at clinical routine is still difficult because it involves complex computational steps with frequent human interactions. In addition, radionomic features differentiating tumour progression and necrosis might also be dependent of the tumour origin and biology. Currently, a distinctive analysis of radiomic features in correlation to their tumour origin is not available. This will be an important topic of our future studies.
In conclusion, we developed a prediction tool using changes in radiomic features extracted from MR scans to distinguish radiation necrosis from tumour progression after brain radiosurgery for metastatic lesions. We found that combination of several delta radiomic features from both T1-weighted postcontrast and T2-weighted MR scans gave rise to the best prediction performance in a RUSBoost ensemble model. This tool may aid decision-making regarding the choice of surgical resection versus conservative medical management for patients suspected of having progression or necrosis after Gamma Knife radiosurgery for brain metastases.
